Fujifilm Diosynth Biotechnologies and Piramal Healthcare UK have entered into a strategic alliance under which the two companies will offer contract development and manufacture of antibody-drug conjugates (ADCs). The alliance aims to provide customers with the experience and assets of both organizations, while simplifying the supply chain and vendor management relationships, for shorter time to clinic.
Fujifilm Diosynth Biotechnologies provides contract development and manufacturing services for biologics, and Piramal is a leader in antibody-drug conjugation. Fujifilm, as part of an ongoing program to expand its mammalian-based biopharma offering, has plans to expand its cGMP manufacturing facilities at both its RTP, NC and Billingham, UK sites.
Stephen Taylor, commercial vice president of Fujifilm Diosynth Biotechnologies, said, “This strategic alliance with Piramal is an important step for us in bringing a new, high-technology offering to the market place. Our customers will benefit from high quality, consistent material, rapid service and shorter logistical chains, saving time on the critical path of drug development. Piramal is a recognized world-leader in this area and we are delighted to be partnering with them.”
Aidan Walker, president of formulations services at Piramal, said, "We are delighted to combine with Fujifilm Diosynth Biotechnologies to offer a seamless service to customers for the production of antibody conjugates. Fujifilm Diosynth Biotechnologies has a long track-record in delivering successful biologics programs, and this alliance will combine strengths from both companies for the benefit of our customers, and ultimately patients.”